Glenmark Pharmaceuticals, a research-driven, global, integrated pharmaceutical organization, has been granted final approval by the United States Food & Drug Administration (FDA) for clobetasol propionate ointment USP, 0.05%, the generic version of Temovate ointment, 0.05% of Fougera Pharmaceuticals.

According to IMS Health sales data for the 12 month period ending January 2017, the Temovate Ointment, 0.05% market achieved annual sales of approximately $175.3 million.

Glenmark’s current portfolio consists of 113 products authorized for distribution in the US marketplace and approximately 64 ANDA’s pending approval with the US FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio. All brand names and trademarks are the property of their respective owners.